Unlike the PD-1/PD-L1 pathway, which plays a central role in regulating T cell exhaustion, the CXCR3 axis can promote the growth of effector T cells and killing of tumor cells, which implies that the CXCR3 axis may impact the effectiveness of tumor immunotherapy. Here, CXCR3 is linked to neoplasm.